Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an 'Outperform' rating on Capricor Therapeutics and raised the price target from $14 to $15.
September 17, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for Capricor Therapeutics and increased the price target from $14 to $15, indicating a positive outlook.
The reaffirmation of an 'Outperform' rating and an increase in the price target by a reputable analyst like Oppenheimer suggests a positive sentiment towards Capricor Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100